合同研究组织正在寻求制药价值链的变革。
Contract Research Organizations Are Seeking Transformation in the Pharmaceutical Value Chain.
作者信息
Huang Jianan
机构信息
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou ZJ571, China.
出版信息
ACS Med Chem Lett. 2019 Mar 13;10(5):684-686. doi: 10.1021/acsmedchemlett.9b00046. eCollection 2019 May 9.
Since the beginning, Contract Research Organizations (CROs) have always faced two core challenges: low profit margin and limited market capitalization. Nowadays, the CRO industry is experiencing a supply chain disruption, driving it to chase the upstream part of the pharmaceutical value chain. A 3P (past, present, prospect) decision-tree model is developed, revealing the future of the CRO industry may be a CRO-Venture model. Perspectives on the potential transformation of CRO industry will contribute to the real-world practice and innovation of this business model.
从一开始，合同研究组织（CRO）就一直面临两个核心挑战：利润率低和市值有限。如今，CRO行业正经历供应链中断，促使其追逐制药价值链的上游部分。本文构建了一个3P（过去、现在、未来）决策树模型，揭示CRO行业的未来可能是CRO-风险投资模式。对CRO行业潜在变革的展望将有助于这一商业模式在现实世界中的实践与创新。
Zotero 插件